PhysIQ and Vital Connect Collaborate to Deliver Home Hospital Pilot Initiative for Patients "Admitted to Home"
Innovative care delivery model leverages continuous biosensor monitoring, advanced physiology analytics, and clinician visits to provide acute care delivery at home
BOSTON – November 15, 2016 – (BUSINESS WIRE)--PhysIQ and Vital Connect, Inc. today announced an initiative to evaluate how clinician visits to home, when coupled with advanced continuous patient monitoring, can potentially replace hospitalizations for common medical admissions. This pilot is taking place at Partners HealthCare Brigham and Women’s Hospital (BWH) and being led by David Levine, MD MA, a physician at BWH.
The Partners HealthCare BWH Home Hospital pilot is the first of two planned initiatives to evaluate how technology and home-based care delivery can be leveraged to treat patients who would otherwise be admitted to the hospital. As part of the randomized controlled trial, patients diagnosed at the BWH Emergency Department with exacerbation of heart failure, pneumonia, COPD, cellulitis, or complicated urinary tract infection are provided with a state-of-the-art home monitoring solution for continuous physiologic insight and daily clinician visits. The technology solution includes the Vital Connect VitalPatch® biosensor that will continuously stream patient vital signs to be analyzed by, and viewable through, the physIQ Personalized Physiology Analytics platform.
“The evolution of digital medicine makes us even more confident in the home hospital model for our patients. The purpose of this study is to show how we can deliver superior outcomes at a lower cost for patients who otherwise would be hospitalized,” said Dr. David Levine, the study’s principal investigator. “We are in a very exciting era of medicine where clinical-grade biosensors and analytics are capable of delivering continuous physiological insight that was traditionally only available in the hospital environment.”
The first phase of the initiative began mid-September 2016 and involves up to 60 patients, half of whom are receiving traditional in-hospital treatment, whereas the other half are receiving treatment at home. Following successful implementation this year, the pilot will scale up to 500 patients in early 2017. The primary aim of the implementation is to demonstrate reduction in hospitalization costs for the at-home population, along with improvement in a series of outcome measures including health-related quality of life, patient safety and quality, and overall patient experience.
“It’s extremely gratifying to know that leading institutions like Partners HealthCare and Brigham and Women’s Hospital are embracing the transformational potential of digital medicine and we are thrilled to be a part of this exciting initiative in collaboration with our partners at Vital Connect,” said Gary Conkright, CEO of physIQ.
Dr. Nersi Nazari, CEO of Vital Connect added, “It’s been our mission from day one to provide clinical-grade physiological data through an FDA-cleared wearable biosensor. We see this initiative as proof of a new era of medicine—one where transformational models of care delivery are enabled by continuous ambulatory monitoring technology.”
PhysIQ is a company dedicated to enabling proactive care delivery models through its proprietary, FDA-cleared Personalized Physiology Analytics technology. PhysIQ is a proven, first-of-its-kind data analytics platform designed to process multiple vital signs from wearable sensors to create a personalized dynamic baseline for each individual. By mapping vital sign relationships this way, physIQ’s analytics detect subtle deviations that may be a precursor to disease exacerbation or change in health. With applications in both healthcare and wellness, physIQ is transforming continuous physiological data into insight for providers, health systems, payers, and pharmaceutical companies. For more information, please visit www.physiq.com.
About Vital Connect, Inc.:
Vital Connect, Inc. is a leader in wearable biosensor technology for wireless hospital and remote patient monitoring. Vital Connect leverages extensive expertise in bioengineering, data analytics, chip design, and mobile and cloud software, creating technology that supports decision-making paradigms to achieve better health and economic outcomes. The Vital Connect® platform is FDA-cleared, CE-marked and Ninsho Certified. It includes the HealthPatch®MD biosensor and in the US and Europe, the single-use VitalPatch® biosensor. Vital Connect products are designed for use in a broad range of inpatient and outpatient settings for hospital, post-discharge, and cardiac monitoring solutions. For more information, please visit www.vitalconnect.com.
Outlook Marketing Services
Christa Carroll, 630-408-9164
Senior Vice President